Back to Search Start Over

Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study

Authors :
Chaney, Aisling M
Lopez-Picon, Francisco R
Serrière, Sophie
Wang, Rui
Bochicchio, Daniela
Webb, Samuel D
Vandesquille, Matthias
Harte, Michael K
Georgiadou, Christina
Lawrence, Catherine
Busson, Julie
Vercouillie, Johnny
Tauber, Clovis
Buron, Frédéric
Routier, Sylvain
Reekie, Tristan
Snellman, Anniina
Kassiou, Michael
Rokka, Johanna
Davies, Karen E
Rinne, Juha O
Salih, Dervis A
Edwards, Frances A
Orton, Llwyd D
Williams, Stephen R
Chalon, Sylvie
Boutin, Hervé
Chaney, Aisling M
Lopez-Picon, Francisco R
Serrière, Sophie
Wang, Rui
Bochicchio, Daniela
Webb, Samuel D
Vandesquille, Matthias
Harte, Michael K
Georgiadou, Christina
Lawrence, Catherine
Busson, Julie
Vercouillie, Johnny
Tauber, Clovis
Buron, Frédéric
Routier, Sylvain
Reekie, Tristan
Snellman, Anniina
Kassiou, Michael
Rokka, Johanna
Davies, Karen E
Rinne, Juha O
Salih, Dervis A
Edwards, Frances A
Orton, Llwyd D
Williams, Stephen R
Chalon, Sylvie
Boutin, Hervé
Publication Year :
2021

Abstract

Mouse models of Alzheimer's disease (AD) are valuable but do not fully recapitulate human AD pathology, such as spontaneous Tau fibril accumulation and neuronal loss, necessitating the development of new AD models. The transgenic (TG) TgF344-AD rat has been reported to develop age-dependent AD features including neuronal loss and neurofibrillary tangles, despite only expressing APP and PSEN1 mutations, suggesting an improved modelling of AD hallmarks. Alterations in neuronal networks as well as learning performance and cognition tasks have been reported in this model, but none have combined a longitudinal, multimodal approach across multiple centres, which mimics the approaches commonly taken in clinical studies. We therefore aimed to further characterise the progression of AD-like pathology and cognition in the TgF344-AD rat from young-adults (6 months (m)) to mid- (12 m) and advanced-stage (18 m, 25 m) of the disease. Methods: TgF344-AD rats and wild-type (WT) littermates were imaged at 6 m, 12 m and 18 m with [18F]DPA-714 (TSPO, neuroinflammation), [18F]Florbetaben (Aβ) and [18F]ASEM (α7-nicotinic acetylcholine receptor) and with magnetic resonance spectroscopy (MRS) and with (S)-[18F]THK5117 (Tau) at 15 and 25 m. Behaviour tests were also performed at 6 m, 12 m and 18 m. Immunohistochemistry (CD11b, GFAP, Aβ, NeuN, NeuroChrom) and Tau (S)-[18F]THK5117 autoradiography, immunohistochemistry and Western blot were also performed. Results: [18F]DPA-714 positron emission tomography (PET) showed an increase in neuroinflammation in TG vs wildtype animals from 12 m in the hippocampus (+11%), and at the advanced-stage AD in the hippocampus (+12%), the thalamus (+11%) and frontal cortex (+14%). This finding coincided with strong increases in brain microgliosis (CD11b) and astrogliosis (GFAP) at these time-points as assessed by immunohistochemistry. In vivo [18F]ASEM PET revealed an age-dependent increase uptake in the striatum and pallidum/nucleus basalis of Meynert in WT

Details

Database :
OAIster
Notes :
text, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1267398754
Document Type :
Electronic Resource